Results 81 to 90 of about 6,725 (159)

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis. [PDF]

Front Oncol
Liang L, Yang B, Wu Y, Liu JL, Liu R, Sun L.   +5 more
europepmc   +1 more source

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSA. [PDF]

Cancers (Basel)
Uccello M, Boussios S, Maï C, Worton H, Bazire A, de Buhren B.   +5 more
europepmc   +1 more source

Niraparib treatment patterns and outcomes in first-line maintenance therapy for ovarian cancer: The RENI-1 study. [PDF]

Chin Med J (Engl)
Zuo J, Wang K, Cui Z, Li Q, Cheng X, Zheng Z, Sun L, Zhang H, Zhang J, Wang S, Cao D, Chen L, Zhao H, Duan W, Zheng M, Shou H, Li J, Wang Y, Chen X, Lin A, Wang H, Zhao L, Hong L, Li L, Wang J, Hu J, Yang H, Wu L.   +27 more
europepmc   +1 more source

Niraparib promotes ferroptosis by inhibiting TM4SF1 expression through ALKBH1-mediated 6mA modification in BRCA wild-type ovarian cancer. [PDF]

Front Pharmacol
Liu PW, Liu ZY, Wu N, Zhang X, Sheng JJ, Zheng SA, Li H.   +6 more
europepmc   +1 more source

PARP inhibitor-based first-line maintenance therapy for newly diagnosed advanced ovarian cancer across molecular subgroups: an updated systematic review and network meta-analysis. [PDF]

Front Oncol
Feng J, Qin X, Mo X.
europepmc   +1 more source

Real-World Risk of Myelodysplastic Syndrome/Acute Myeloid Leukemia and Other Second Primary Malignancies in Patients with Epithelial Ovarian Cancer Treated with Niraparib Maintenance Therapy: Results from a Postauthorization Safety Study. [PDF]

Adv Ther
van der Vorst MJDL, Maximiano Alonso C, Calderón Boyle TA, Schilder JM, Malinowska IA, Ye G, Kroep JR, Mañé Martínez JM, Kuplast J, Perhanidis J, Evans C, Golembesky AK, Tasca G, Kommoss S.   +13 more
europepmc   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. [PDF]

Adv Sci (Weinh)
Li H, Xiang M, Xu Q, Liu J, Jiao X, Mu W, Lv X, Tao K, Xu Y, Zhou D, Gong W, Yan D, Hu Y, Xu S, Zhao B, Li J, Gai Y, Hu G, Zhu L, Gao Q, Fang Y.   +20 more
europepmc   +1 more source

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment. [PDF]

Front Pharmacol
Pokladyuk A, Voronova V, Helmlinger G, Peskov K, Kosinsky Y.   +4 more
europepmc   +1 more source

Progression-free survival outcomes of PARP inhibitors in ovarian cancer: an exploratory analysis of treatment heterogeneity based on organ vulnerability. [PDF]

Front Oncol
Zhou X, Xiong X, Yang Z, Cao Z, Ni Q.
europepmc   +1 more source

PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies. [PDF]

Front Cell Dev Biol
Ouhajjou A, Mazouji O, Nejjari C, Incitti R, Mansour H.   +4 more
europepmc   +1 more source